Frankfurt | Reuters — Bayer is considering job cuts and outsourcing as part of a wide-ranging review of drug research and development that will last until at least November, a person familiar with the company told Reuters. The prospect of “very tangible changes” contributed to a decision by key board members to extend the contract […] Read more
